Trulieve Cannabis (TRLV) Aktienübersicht
Trulieve Cannabis Corp. ist als Cannabis-Einzelhändler in den Vereinigten Staaten tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 6/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 4/6 |
| Dividenden | 0/6 |
TRLV Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Trulieve Cannabis Corp. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$11.60 |
| 52-Wochen-Hoch | US$13.28 |
| 52-Wochen-Tief | US$4.62 |
| Beta | 1.76 |
| 1 Monat Veränderung | 20.21% |
| 3 Monate Veränderung | 22.75% |
| 1 Jahr Veränderung | 65.24% |
| 3 Jahre Veränderung | 82.53% |
| 5 Jahre Veränderung | -55.96% |
| Veränderung seit IPO | -0.64% |
Aktuelle Nachrichten und Updates
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking Alpha
TRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.
Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?Recent updates
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Summary Trulieve Cannabis Corp. is reinitiated as a Buy, driven by regulatory catalysts and attractive valuation after a recent 81% rally. Rescheduling of medicinal cannabis to Schedule III eliminates punitive tax burdens, boosts cash flows, and enables greater R&D and financing flexibility for TRLV. TRLV is well-positioned for growth through Florida consolidation, expansion into Texas and Alabama, and potential upside from a $583M tax liability reversal. Trading at a forward EV/EBITDA of 6.92 versus a sector median of 12.5, TRLV offers compelling value and strong balance sheet support amid competitive risks. Read the full article on Seeking AlphaTRLV: Federal Rescheduling And NYSE Listing Will Support Future Upside Potential
Analysts recently trimmed their fair value estimate for Trulieve Cannabis from about $19.42 to roughly $18.18, citing updated assumptions around discount rates, revenue trends, profit margins, and future P/E multiples. These changes align with a new $15 analyst price target and expectations for the company to benefit from U.S. medical cannabis growth following federal rescheduling.Rescheduling Tailwinds And Medical Expansion Will Reinforce Long Term Earnings Power
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a large vertically integrated medical cannabis platform in the U.S., focused on branded products sold through its own retail network and wholesale partners. What are the underlying business or industry changes driving this perspective?
TRLV: Federal Rescheduling And Georgia Expansion Will Drive Future Upside
Analysts have adjusted their fair value estimate for Trulieve Cannabis from $17.25 to $15.00, citing updated assumptions on revenue trends, profit margins, and future P/E that align with recent Street research and a new $15 price target. Analyst Commentary Recent Street research on Trulieve Cannabis emphasizes both the potential upside tied to regulatory shifts and the risks that could keep the stock under pressure.TRLV: Georgia Expansion And Schedule III Pathway Will Support Future Upside
Analysts have raised their price target on Trulieve Cannabis to $17.25 from $14.08, citing updated assumptions around profit margin, P/E expectations, and other valuation drivers. What’s in the News for Trulieve Cannabis Trulieve Cannabis marked the expansion of Georgia’s medical cannabis program with a ceremonial first sale at its Marietta dispensary under the new "Putting Georgia's Patients First Act." The act allows flower and vaporization products for patients aged 21 and older and broadens qualifying conditions such as lupus, HIV, and inflammatory bowel disease (source: company announcement).Rescheduling Uncertainty And Texas Execution Risks Will Pressure Results Yet Support Long Term Upside
Catalysts About Trulieve Cannabis Trulieve Cannabis operates a vertically integrated cannabis business focused primarily on medical patients across several U.S. states. What are the underlying business or industry changes driving this perspective?TRLV: NYSE Listing And Buybacks Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Trulieve Cannabis from $21.00 to approximately $19.42, citing updated assumptions about long-term profit margins and a slightly lower future P/E multiple. What’s in the News for Trulieve Cannabis Trulieve Cannabis listed on the New York Stock Exchange under the ticker TRLV, becoming the first U.S. based marijuana company on the NYSE after a federal rescheduling of medical marijuana to Schedule III, according to recent news coverage.Trulieve Cannabis (TRLV) Stock Could Be 51.9% Undervalued After NYSE Listing
Trulieve Cannabis (TRLV) has become the first U.S. marijuana company to trade on the New York Stock Exchange, following the federal reclassification of medical marijuana, which opened the door to its uplisting. See our latest analysis for Trulieve Cannabis. The recent NYSE listing comes after a 34.67% 1 month share price return and a 58.56% 3 month share price return. The 1 year total shareholder return of 193.08% and 3 year total shareholder return of 155.70% contrast with a 5 year total...Federal Rescheduling And Medical Expansion Will Support A Stronger Long Term Cannabis Operator
Catalysts About Trulieve Cannabis Trulieve Cannabis operates cannabis cultivation, production and retail operations serving primarily medical patients across multiple U.S. states. What are the underlying business or industry changes driving this perspective?Aktionärsrenditen
| TRLV | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | -6.7% | -0.6% | -1.6% |
| 1Y | 65.2% | 45.2% | 12.1% |
Rendite im Vergleich zur Industrie: TRLV übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 45.2 erzielte.
Rendite vs. Markt: TRLV übertraf den Markt US, der im vergangenen Jahr eine Rendite von 12.1 erzielte.
Preisvolatilität
| TRLV volatility | |
|---|---|
| TRLV Average Weekly Movement | 8.6% |
| Pharmaceuticals Industry Average Movement | 8.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.2% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: TRLV hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: TRLVDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 16% auf 9% zurückgegangen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. ist als Cannabis-Einzelhändler in den Vereinigten Staaten tätig. Das Unternehmen kultiviert, verarbeitet und produziert Cannabisprodukte und vertreibt seine Produkte an seine Apotheken sowie durch Hauslieferungen. Es verkauft Blumen, Esswaren, Vapes, orale, topische Produkte, Konzentrate und Zubehör unter den Marken Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors und Roll One.
Trulieve Cannabis Corp.'s Grundlagenzusammenfassung
| TRLV grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.24b |
| Gewinn(TTM) | -US$467.83m |
| Umsatz(TTM) | US$1.14b |
Ist TRLV zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| TRLV Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$1.14b |
| Kosten der Einnahmen | US$461.65m |
| Bruttogewinn | US$677.39m |
| Sonstige Ausgaben | US$1.15b |
| Gewinn | -US$467.83m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.43 |
| Bruttomarge | 59.47% |
| Nettogewinnspanne | -41.07% |
| Schulden/Eigenkapital-Verhältnis | 37.9% |
Wie hat sich TRLV auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/15 09:10 |
| Aktienkurs zum Tagesende | 2026/09/15 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Trulieve Cannabis Corp. wird von 16 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Matt Bottomley | Canaccord Genuity |